American Academy of Pediatrics (AAP): Latest Guidance on Nirsevimab and Other Resources to Prepare for Respiratory Syncytial Virus (RSV)

New products for the prevention of severe RSV disease in children have recently been approved or are expected to be approved soon by the Food and Drug Administration (FDA). Pediatric practices should understand the products, when to recommend/administer them and prepare offices for their availability.

Read the full guidance from the AAP.